We are experts in myeloma…
it’s all we do

 

Our singular focus on myeloma ensures that we bring unparalleled expertise and dedication to everything we do

 

From actionable insights to strategic engagement with leading KOLs and community clinicians, our full suite of  services empowers you to lead in the myeloma market

Everything you need to navigate the myeloma market

Insights

MYInsights provides real-time insights to data being presented at conferences or from the latest publications. Gain an understanding of how the experts view the data.

Data Compass conference reports. Collecting insights at medical conferences shouldn’t be hard. MYELOMA360 makes it easy!

Engagements

MYBoard is a new format for Advisory Boards.

In place of single company events, MYBoard is an independent full day advisory board fully managed by MYELOMA360, with four 2-hour time slots for multiple companies, allowing for a focused, efficient, dedicated session to generate insights around your strategic objectives.

Strategy & Consulting

We are a team of seasoned biopharmaceutical specialists dedicated to helping companies strategize and plan their marketing, clinical development and medical affairs activities.

Our expertise is focused in myeloma across the full development lifecycle, allowing us to provide tailored solutions to drive your company’s success.

Everything you need to navigate the myeloma market

Latest insights

Myeloma News

Source: Pharmacy Times articles Post Content Read More

New center promotes advocacy for gynecological cancer patients

The Ovarian Cancer Research Alliance (OCRA) launched a project to push lawmakers to enact legislation that will improve the lives of people affected by ovarian cancer and other types of gynecological cancers. OCRA’s new Center for Public Policy is a dedicated arm of...

FDA clears Thermo Fisher EXTENT system for myeloma diagnosis

Thermo Fisher Scientific has received U.S. Food and Drug Administration (FDA) clearance for its EXENT System, an automated test that helps doctors diagnose multiple myeloma. The system detects and identifies abnormal antibodies called M-proteins, which are produced by...
Latest Data

Latest Publications

Inflammatory markers from routine blood tests predict survival in multiple myeloma: a Systematic Review and meta-analysis

Front Immunol. 2025 Oct 30;16:1669878. doi: 10.3389/fimmu.2025.1669878. eCollection 2025. ABSTRACT...

The challenge of non-transplant eligible, newly diagnosed multiple myeloma

Leuk Lymphoma. 2025 Oct;66(10):1767-1777. doi: 10.1080/10428194.2025.2513676. Epub 2025 Jun 3....

Optimizing oncology drug development: systematic review of 22 years of myeloma randomized controlled trials

J Natl Cancer Inst. 2025 Nov 9:djaf326. doi: 10.1093/jnci/djaf326. Online ahead of print. ABSTRACT...

Efficacy of novel therapies for refractory and relapsed multiple myeloma in China: A scoping systematic review

Chin Med J (Engl). 2025 Oct 31. doi: 10.1097/CM9.0000000000003832. Online ahead of print. NO...

Email

info@myeloma360.com